Anti-tmem106b antibodies and methods of use thereof
AssigneeAlector LLC
InventorsEric BROWN, Angie Grace YEE, Tina SCHWABE, Herve RHINN, Arnon ROSENTHAL
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Claims29
An isolated anti-TMEM106B antibody, wherein the anti-TMEM106B antibody comprises at least one, two, three, four, five, or six HVRs of an antibody selected from the group consisting of:
- TM-54, TM-56, TM-59, TM-60, TM-61, TM-62, TM-63, TM-64, TM-65, TM-66, TM-70, TM-72, TM-73, TM-74, TM-76, TM-77, TM-78, TM-79, TM-80. TM-82, TM-83, TM-84, TM-85, TM-86, TM-87, TM-88, TM-90, TM-91, TM-92, TM-93, and TM-94, optionally wherein the HVRs are the Kabat, AbM, Chothia, or Contact CDRs.
An isolated antibody that binds to human TMEM106B, wherein the antibody comprises a heavy chain variable region and a light chain variable region,
- wherein the heavy chain variable region comprises:
- an HVR-H1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:77-106;
- an HVR-H2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:107-142;
- and
- an HVR-H3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:143-175;
- and
- wherein the light chain variable region comprises:
- an HVR-L1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:176-208;
- an HVR-L2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:209-231;
- and
- an HVR-L3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:232-263.
Dependencies are inferred from the claim text.